Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H223
UPID:
EHD4_HUMAN
Alternative names:
Hepatocellular carcinoma-associated protein 10/11; PAST homolog 4
Alternative UPACC:
Q9H223; Q9HAR1; Q9NZN2
Background:
EH domain-containing protein 4, also known as Hepatocellular carcinoma-associated protein 10/11 and PAST homolog 4, is a pivotal ATP- and membrane-binding protein. It plays a crucial role in controlling membrane reorganization and tubulation upon ATP hydrolysis, significantly impacting early endosomal transport.
Therapeutic significance:
Understanding the role of EH domain-containing protein 4 could open doors to potential therapeutic strategies.